Chapter 32 – Obesity in Hypertension

[1]  P. Mitchell,et al.  Body mass index and waist circumference are associated with blood pressure in preschool-aged children. , 2011, Annals of epidemiology.

[2]  C. Tsioufis,et al.  Pathophysiology of Resistant Hypertension: The Role of Sympathetic Nervous System , 2011, International journal of hypertension.

[3]  P. Deedwania.  Hypertension, Dyslipidemia, and Insulin Resistance in Patients With Diabetes Mellitus or the Cardiometabolic Syndrome: Benefits of Vasodilating β‐Blockers , 2011, Journal of clinical hypertension.

[4]  A. Beleigoli,et al.  Natriuretic peptides: linking heart and adipose tissue in obesity and related conditions – a systematic review , 2009, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[5]  N. Nguyen,et al.  Resolution of Systemic Hypertension after Laparoscopic Gastric Bypass , 2009, Journal of Gastrointestinal Surgery.

[6]  G. Bakris,et al.  Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. , 2008, The New England journal of medicine.

[7]  L. Lönn,et al.  Hydrochlorothiazide, but not Candesartan, Aggravates Insulin Resistance and Causes Visceral and Hepatic Fat Accumulation: The Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) Study , 2008, Hypertension.

[8]  J. Cutler,et al.  Trends in Hypertension Prevalence, Awareness, Treatment, and Control Rates in United States Adults Between 1988–1994 and 1999–2004 , 2008, Hypertension.

[9]  G. Bakris,et al.  ASH Position Paper: Treatment of Hypertension in Patients With Diabetes—An Update , 2008, Journal of clinical hypertension.

[10]  Zhi-Hong Liu,et al.  Obesity-related glomerulopathy in China: a case series of 90 patients. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  F. Salvi,et al.  Renin–angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans , 2008, Journal of hypertension.

[12]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[13]  D. Sica,et al.  Centrally Acting Antihypertensive Agents: An Update , 2007, Journal of clinical hypertension.

[14]  R. Brook,et al.  Blood pressure and vascular effects of leptin in humans. , 2007, Metabolic syndrome and related disorders.

[15]  U. Pagotto,et al.  The Hypothalamic‐Pituitary‐Adrenal Axis Activity in Obesity and the Metabolic Syndrome , 2006, Annals of the New York Academy of Sciences.

[16]  R. Elston,et al.  Plasma Aldosterone Is Independently Associated With the Metabolic Syndrome , 2006, Hypertension.

[17]  K. Reynolds,et al.  Body weight and mortality among men and women in China. , 2006, JAMA.

[18]  R. Fogari,et al.  Effects of Doxazosin and Irbesartan on Blood Pressure and Metabolic Control in Patients with Type 2 Diabetes and Hypertension , 2005, Journal of cardiovascular pharmacology.

[19]  B. Swinburn,et al.  Effect of orlistat on cardiovascular disease risk in obese adults , 2005, Diabetes, obesity & metabolism.

[20]  C. Berne.  A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[21]  Arya M. Sharma,et al.  Weight Loss and the Renin-Angiotensin-Aldosterone System , 2005, Hypertension.

[22]  A. F. Mackintosh,et al.  Sympathetic Neural Activation in Nondiabetic Metabolic Syndrome and Its Further Augmentation by Hypertension , 2004, Hypertension.

[23]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[24]  T. Ogihara,et al.  Association of Hypoadiponectinemia With Impaired Vasoreactivity , 2003, Hypertension.

[25]  G. Mancia,et al.  Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study , 2003, Journal of hypertension.

[26]  L. Wilkins.  Diuretic Versus &agr;-Blocker as First-Step Antihypertensive Therapy: Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2003 .

[27]  K. Chayama,et al.  Effect of Different Intensities of Exercise on Endothelium-Dependent Vasodilation in Humans: Role of Endothelium-Dependent Nitric Oxide and Oxidative Stress , 2003, Circulation.

[28]  S. Oparil.  Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Practical Implications , 2003, Hypertension.

[29]  Victor J Stevens,et al.  Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. , 2003, JAMA.

[30]  E. Blaak,et al.  Possible involvement of the adipose tissue renin‐angiotensin system in the pathophysiology of obesity and obesity‐related disorders , 2003, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[31]  Abdullah Al Mamun,et al.  Obesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis , 2003, Annals of Internal Medicine.

[32]  G. Bakris,et al.  Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension , 2002, Journal of hypertension.

[33]  Arya M. Sharma,et al.  Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension , 2002, Journal of hypertension.

[34]  Heinrich Taegtmeyer,et al.  Obesity and the risk of heart failure. , 2002, The New England journal of medicine.

[35]  J. Carroll,et al.  Exercise training in obesity lowers blood pressure independent of weight change. , 2002, Medicine and science in sports and exercise.

[36]  H. Raff,et al.  OXIDIZED PRODUCTS OF LINOLEIC ACID STIMULATE ADRENAL STEROIDOGENESIS , 2002, Endocrine research.

[37]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[38]  L. Sjöström,et al.  The Swedish Obese Subjects (SOS) study—rationale and results , 2001, International Journal of Obesity.

[39]  G. Bray,et al.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .

[40]  N. Milas,et al.  Long-Term Weight Loss and Changes in Blood Pressure: Results of the Trials of Hypertension Prevention, Phase II , 2001, Annals of Internal Medicine.

[41]  T. Young,et al.  Longitudinal study of moderate weight change and sleep-disordered breathing. , 2000, JAMA.

[42]  J. Hayano,et al.  Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning. , 2000, Archives of internal medicine.

[43]  H Wedel,et al.  Differentiated long-term effects of intentional weight loss on diabetes and hypertension. , 2000, Hypertension.

[44]  P. Whelton,et al.  Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. , 2000, Hypertension.

[45]  P. Whelton,et al.  Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. , 1998, JAMA.

[46]  G. Bray,et al.  A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. , 1997, The New England journal of medicine.

[47]  R N Pierson,et al.  How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? , 1996, American journal of epidemiology.

[48]  S. Kjeldsen,et al.  The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. , 1994, Blood pressure.

[49]  J. Hall,et al.  Louis K. Dahl Memorial Lecture. Renal and cardiovascular mechanisms of hypertension in obesity. , 1994, Hypertension.

[50]  J. Cutler,et al.  Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. , 1993, JAMA.

[51]  N. Cook,et al.  Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. , 1993, Archives of internal medicine.

[52]  V. Campese,et al.  Role of sympathetic nerve inhibition and body sodium-volume state in the antihypertensive action of clonidine in essential hypertension. , 1980, Kidney international.

[53]  Y. Nakashima,et al.  Long-term treatment with imidapril but not with nifedipine enhances plasma NOx concentration in patients with essential hypertension. , 2006, Journal of pharmacological sciences.

[54]  J. Guízar,et al.  Sympathetic activity and response to ACE inhibitor (enalapril) in normotensive obese and non-obese subjects. , 2004, Archives of medical research.

[55]  P. Weidmann,et al.  Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension , 2004, European Journal of Clinical Pharmacology.

[56]  A. Siani,et al.  Plasma leptin and blood pressure in men: graded association independent of body mass and fat pattern. , 2003, Obesity research.

[57]  Arya M. Sharma,et al.  The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension , 2001, Journal of Molecular Medicine.

[58]  M. Blaufox,et al.  The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. , 1992, Archives of internal medicine.

[59]  A. Gupta,et al.  Effects of insulin on renal sodium excretion. , 1992, Hypertension.